Widely used:Recently Viewed
Clear All
$23 Mln
--
1.22
--
0
-145.39 %
--
0 %
2.3
-5179800
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
| -26.16 | -22.20 | -38.93 | -24.17 | -83.43 | -73.77 | -- |
|
BSE Sensex*
| 12.20 | -0.16 | 1.32 | 22.81 | 11.05 | 16.56 | 11.80 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
| -35.59 | -98.04 | -76.76 | -40.00 | -56.78 | -89.68 | 1.34 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$23.17 Mln
$0.00 Mln
$0.00 Mln
$27.93 Mln
$0.17 Mln
High
$2.56 - 6.75
8,486,800
NASDAQ: NRBO
Cambridge, MA
https://www.neurobopharma.com
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with... development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. Read more
The total asset value of Neurobo Pharmaceuticals Inc (NRBO) stood at $ 38 Mln as on 30-Jun-24
The share price of Neurobo Pharmaceuticals Inc (NRBO) is $2.73 (NASDAQ) as of 04-Oct-2024 16:00 EDT. Neurobo Pharmaceuticals Inc (NRBO) has given a return of -83.43% in the last 3 years.
Neurobo Pharmaceuticals Inc (NRBO) has a market capitalisation of $ 23 Mln as on 04-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Neurobo Pharmaceuticals Inc (NRBO) is 1.22 times as on 04-Oct-2024, a 61% discount to its peers’ median range of 3.12 times.
Since, TTM earnings of Neurobo Pharmaceuticals Inc (NRBO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Neurobo Pharmaceuticals Inc (NRBO) and enter the required number of quantities and click on buy to purchase the shares of Neurobo Pharmaceuticals Inc (NRBO).
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
The CEO & director of Mr. Hyung-Heon Kim. is Neurobo Pharmaceuticals Inc (NRBO), and CFO & Sr. VP is Mr. Hyung-Heon Kim.
There is no promoter pledging in Neurobo Pharmaceuticals Inc (NRBO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,034
|
|
|
1,002
|
|
|
998
|
|
|
875
|
| Neurobo Pharmaceuticals Inc (NRBO) | Ratios |
|---|---|
|
Return on equity(%)
|
-145.39
|
|
Operating margin(%)
|
-663150
|
|
Net Margin(%)
|
-647475
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Neurobo Pharmaceuticals Inc (NRBO) was $0 Mln.
$0.08
